VITA 34 International AG: Diabetes Research Institute received IND approval for a clinical study in newly manifested Type 1 Diabetes children using autologous 'Nabelschnurblut VITA34'

(PresseBox) ( Leipzig, )
VITA 34 International AG (ISIN DE000A0BL849), the parent company of the leading private umbilical cord blood bank in the German-speaking countries VITA 34, received IND approval of its autologous Cord Blood for a clinical study in children with Type 1 Diabetes. The study will be performed by the Diabetes Research Institute of the Klinik und Poliklinik für Kinder- und Jugendmedizin of the Technical University Munich. A corresponding approval was granted by The Paul-Ehrlich-Institute, a high federal agency in Germany. The aim of the study is to investigate the safety and potential benefit of transfusing autologous Cord Blood in children who have newly manifested Type 1 Diabetes. The study is designed to last 24 months and will be controlled by a reference group. The risk of Type 1 Diabetes in Germany is about 1 in 600 by the age of fourteen. A similar pilot study in the USA shows promising results with regard to the disturbed immune balance, insulin requirements, and the quality of metabolic control.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to